Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Common Equity (2020 - 2025)

Insight Molecular Diagnostics' Common Equity history spans 6 years, with the latest figure at -$9.2 million for Q3 2025.

  • For Q3 2025, Common Equity fell 194.7% year-over-year to -$9.2 million; the TTM value through Sep 2025 reached -$9.2 million, down 194.7%, while the annual FY2024 figure was -$12.3 million, 159.97% down from the prior year.
  • Common Equity for Q3 2025 was -$9.2 million at Insight Molecular Diagnostics, down from $1.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $106.6 million in Q1 2021 and bottomed at -$12.3 million in Q4 2024.
  • The 5-year median for Common Equity is $36.1 million (2023), against an average of $42.0 million.
  • The largest annual shift saw Common Equity soared 191.13% in 2021 before it crashed 194.7% in 2025.
  • A 5-year view of Common Equity shows it stood at $65.2 million in 2021, then crashed by 47.42% to $34.3 million in 2022, then crashed by 40.31% to $20.5 million in 2023, then plummeted by 159.97% to -$12.3 million in 2024, then grew by 25.08% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Common Equity are -$9.2 million (Q3 2025), $1.1 million (Q2 2025), and $10.2 million (Q1 2025).